IBO
Impact Biomedical Inc
$
0.550
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.5515
Open
0.540
VWAP
0.54
Vol
59.69K
Mkt Cap
6.71M
Low
0.540
Amount
32.45K
EV/EBITDA(TTM)
--
Total Shares
12.19M
EV
32.59M
EV/OCF(TTM)
--
P/S(TTM)
--
Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies.
Show More
Valuation Metrics
The current forward P/E ratio for Impact Biomedical Inc (IBO.A) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Impact Biomedical Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.02
Current PS
0.55
Overvalued PS
0.12
Undervalued PS
-0.08
Financials
Annual
Quarterly
FY2025Q3
18.00K
Total Revenue
FY2025Q3
YoY :
-15.88%
-948.00K
Operating Profit
FY2025Q3
YoY :
-100.00%
N/A
Net Income after Tax
FY2025Q3
YoY :
-300.00%
-0.12
EPS - Diluted
FY2025Q2
YoY :
+4.20%
-694.00K
Free Cash Flow
FY2025Q2
-4.17K
Gross Profit Margin - %
FY2025Q2
N/A
FCF Margin - %
FY2025Q2
-205.03K
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
7.3M
USD
13
0-12
Months
58.0
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
1
310.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
7.3M
USD
13
0-12
Months
58.0
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
1
310.0
USD
Months
0-12
0
0.0
USD
Months
IBO News & Events
Events Timeline
2025-08-18 (ET)
2025-08-18
08:38:26
Impact BioMedical Reveals U.S. Patent Issuance for 3F
2025-06-23 (ET)
2025-06-23
07:55:08
Impact BioMedical, Dr Ashleys enter strategic merger agreement
2025-02-26 (ET)
2025-02-26
08:40:42
Impact BioMedical announces acquisition of Celios in $1.15M equity transaction
Sign Up For More Events
Sign Up For More Events
News
9.0
08-18NewsfilterImpact Biomedical Inc (IBO) Announces Issuance of US Patent for 3F™
9.5
06-25BenzingaWhy BlackBerry Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
9.0
06-24BenzingaWhy Nektar Therapeutics Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket
Sign Up For More News
People Also Watch
FAQ
What is Impact Biomedical Inc (IBO) stock price today?
The current price of IBO is 0.5505 USD — it has increased 3.18 % in the last trading day.
What is Impact Biomedical Inc (IBO)'s business?
What is the price predicton of IBO Stock?
What is Impact Biomedical Inc (IBO)'s revenue for the last quarter?
What is Impact Biomedical Inc (IBO)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Impact Biomedical Inc (IBO)'s fundamentals?
How many employees does Impact Biomedical Inc (IBO). have?